Literature DB >> 12590329

The humoral immune response in melioidosis patients during therapy.

C Vasu1, J Vadivelu, S D Puthucheary.   

Abstract

BACKGROUND: This study was undertaken to identify and quantify the class and subclass antibody responses to the culture filtrate antigen (CFA) of Burkholderia pseudomallei in melioidosis patients under long-term maintenance or eradication therapy.
MATERIALS AND METHODS: Sequential sera samples from seven melioidosis patients collected between January 1992 and April 1998 were analyzed for immunoglobulin (Ig) types and IgG isotypes by ELISA using B. pseudomallei CFA.
RESULTS: Melioidosis patients generated a strong IgG, IgA and IgM response to the CFA of B. pseudomallei throughout the infection and IgG1 and IgG2 were the predominant IgG istotypes produced. Although high levels of these antibodies were detected in all the seven patients, the IgG, IgG1 and IgG2 antibodies showed a consistent response and good correlation with the clinical history in all cases.
CONCLUSION: This study suggests that monitoring IgG antibody or IgG1 or IgG2 isotype antibody levels to CFA in patients under maintenance or eradication antibiotic therapy may be useful as a tool to detect the status of infection and as a guideline to determine the duration of maintenance antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12590329     DOI: 10.1007/s15010-002-3020-2

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

Review 1.  Environmental factors that affect the survival and persistence of Burkholderia pseudomallei.

Authors:  Timothy J J Inglis; Jose-Luis Sagripanti
Journal:  Appl Environ Microbiol       Date:  2006-09-15       Impact factor: 4.792

Review 2.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

Review 3.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

4.  Evaluation of immunoglobulin M (IgM) and IgG rapid cassette test kits for diagnosis of melioidosis in an area of endemicity.

Authors:  Vanaporn Wuthiekanun; Premjit Amornchai; Wirongrong Chierakul; Allen C Cheng; Nicholas J White; Sharon J Peacock; Nicholas P J Day
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 5.  The art of persistence-the secrets to Burkholderia chronic infections.

Authors:  Eric R G Lewis; Alfredo G Torres
Journal:  Pathog Dis       Date:  2016-07-19       Impact factor: 3.166

Review 6.  Melioidosis.

Authors:  W Joost Wiersinga; Harjeet S Virk; Alfredo G Torres; Bart J Currie; Sharon J Peacock; David A B Dance; Direk Limmathurotsakul
Journal:  Nat Rev Dis Primers       Date:  2018-02-01       Impact factor: 52.329

7.  Development of vaccines against burkholderia pseudomallei.

Authors:  Natasha Patel; Laura Conejero; Melanie De Reynal; Anna Easton; Gregory J Bancroft; Richard W Titball
Journal:  Front Microbiol       Date:  2011-09-27       Impact factor: 5.640

8.  Global transcriptional analysis of Burkholderia pseudomallei high and low biofilm producers reveals insights into biofilm production and virulence.

Authors:  Chui-Yoke Chin; Yuka Hara; Ahmad-Kamal Ghazali; Soon-Joo Yap; Cin Kong; Yee-Chin Wong; Naufal Rozali; Seng-Fook Koh; Chee-Choong Hoh; Savithri D Puthucheary; Sheila Nathan
Journal:  BMC Genomics       Date:  2015-06-20       Impact factor: 3.969

Review 9.  Burkholderia vaccines: are we moving forward?

Authors:  Leang-Chung Choh; Guang-Han Ong; Kumutha M Vellasamy; Kaveena Kalaiselvam; Wen-Tyng Kang; Anis R Al-Maleki; Vanitha Mariappan; Jamuna Vadivelu
Journal:  Front Cell Infect Microbiol       Date:  2013-02-05       Impact factor: 5.293

Review 10.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.